Jim Roumell
Latest Articles
Enzo Biochem Trades At A Discount To Its Sum Of The Parts Value With Multiple Ways To Win
Hallmark Financial Services: An Overlooked Turnaround Story Trading At A Discount To Book Value
Dundee: An Under The Radar Holding Company Trading At A Significant Discount To Conservative NAV
Oxford Square Capital: Substantial Discount To NAV With Double-Digit Distribution Yield
Rubicon Project Has Turned The Corner And Is Now Well Positioned As A Leading Marketplace
Medley Capital More Attractive After Recent Pullback, Given Large Discount To Conservative NAV
Medley Capital: Discount To NAV Remains But Not For Long
Successful Turnaround Continues At SeaChange International On Its Path To A Potential Sale
Marchex: Significant Improvement In Financials Yet Stock Still Trades At Extremely Low Enterprise Valuation
Continued Positive Results, Strong Balance Sheet And Attractive Business Model Validate Long Thesis On Sandstorm Gold
Medley Capital: Discount To NAV Even Under Conservative Assumptions Plus 11% Yield
Activist Investor Is Catalyst To Unlock Significant Value At Edgewater Technology
Liquidity Services Is Out Of Favor, Overlooked, Misunderstood And Undervalued
Sandstorm Gold Trades At A Significant Discount To SOTP With Multiple Catalysts
SeaChange International: Strong Balance Sheet Provides Floor Until Eventual Sale Of Company
Marchex: Asymmetric Opportunity Due To Overlooked And Growing Analytics Business With Strong Balance Sheet
Encouraging Results From Rosetta Stone Strengthen Bullish Case
Rapid7 Is Cash-Rich, Debt-Free, Growing >20% And Trades At A Discount To M&A Comps
SA Interview: Deep Value Investing With Jim Roumell
Rubicon Project Trades At A Distressed Multiple With A Strong Balance Sheet, Product And Management
Exclusive Interview With GSI Technology Management
Exclusive Interview With Rosetta Stone Chairman And CEO
WCI Communities: Niche Homebuilder Trading Below Understated Book Value
GSI Technology Offers A Free Call Option On New Technology With Strong Balance Sheet And Dominant Position In Niche Market
Rosetta Stone Is On Track To Be Sold Within 12 To 18 Months
Nuveen Credit Strategies Income Fund: Opportunistically Investing In Double-Discount Closed-End Funds
Rosetta Stone: Still A High Conviction Buy As SOTP Thesis Remains Intact
Paratek Pharmaceuticals: Totally Mispriced Antibiotic Company With Strong Data Supporting Likely Phase 3 Success
Liquidity Services' Price Trumps Immediate Outlook
DSP Group Trades At A Compelling Valuation With A Fortress-Like Balance Sheet And An Underappreciated Growth Story
Covisint: Investment Thesis Remains Intact
Rosetta Stone Turnaround Gaining Traction